We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+2.78%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.04B
AUM Growth
-$13.5M
Cap. Flow
+$810K
Cap. Flow %
0.08%
Top 10 Hldgs %
35.44%
Holding
98
New
14
Increased
36
Reduced
31
Closed
5

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$31.8M
2
DHR icon
Danaher
DHR
+$9.47M
3
EW icon
Edwards Lifesciences
EW
+$8.63M
4
ELV icon
Elevance Health
ELV
+$8.62M
5
GILD icon
Gilead Sciences
GILD
+$7.44M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$21.7M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$20.8M
3
THC icon
Tenet Healthcare
THC
+$18.2M
4
MDT icon
Medtronic
MDT
+$9.59M
5
ZBH icon
Zimmer Biomet
ZBH
+$8.91M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VKTX icon
51
Viking Therapeutics
VKTX
$3.98B
$6.1M 0.59%
115,000
-30,000
-21% -$1.97M
GKOS icon
52
Glaukos
GKOS
$10.7B
$5.92M 0.57%
50,000
+23,000
+85% +$2.44M
MRUS
53
DELISTED
Merus
MRUS
$5.35M 0.51%
+90,500
New +$4.38M
EHC icon
54
Encompass Health
EHC
$12.4B
$5.15M 0.49%
60,000
+31,000
+107% +$2.6M
SNDX icon
55
Syndax Pharmaceuticals
SNDX
$1.81B
$4.69M 0.45%
228,500
+50,000
+28% +$1.05M
BBIO icon
56
BridgeBio Pharma
BBIO
$16.7B
$4.67M 0.45%
184,500
+80,000
+77% +$2.19M
MIRM icon
57
Mirum Pharmaceuticals
MIRM
$5.95B
$4.59M 0.44%
134,250
+42,000
+46% +$1.1M
JANX icon
58
Janux Therapeutics
JANX
$999M
$4.48M 0.43%
106,847
+2,347
+2% +$110K
ANNX icon
59
Annexon
ANNX
$875M
$4.41M 0.42%
+900,000
New +$4.65M
ESPR
60
DELISTED
Esperion Therapeutics
ESPR
$4.38M 0.42%
+1,975,000
New +$4.65M
EPIX
61
DELISTED
ESSA Pharma
EPIX
$4.24M 0.41%
806,054
-105,766
-12% -$672K
XNCR icon
62
Xencor
XNCR
$1.58B
$4.14M 0.4%
218,750
– –
PEN icon
63
Penumbra
PEN
$12.9B
$4.14M 0.4%
23,000
-23,000
-50% -$4.59M
TGTX icon
64
TG Therapeutics
TGTX
$7.53B
$3.8M 0.36%
213,500
+90,000
+73% +$1.44M
NRIX icon
65
Nurix Therapeutics
NRIX
$2.67B
$3.64M 0.35%
+174,393
New +$2.72M
ALKS icon
66
Alkermes
ALKS
$8.27B
$3.62M 0.35%
150,000
+40,000
+36% +$981K
KRYS icon
67
Krystal Biotech
KRYS
$9.69B
$3.49M 0.34%
19,000
– –
IMVT icon
68
Immunovant
IMVT
$8.19B
$3.45M 0.33%
130,500
+5,000
+4% +$142K
KURA icon
69
Kura Oncology
KURA
$843M
$3.43M 0.33%
166,526
– –
STAA icon
70
STAAR Surgical
STAA
$1.26B
$3.09M 0.3%
+65,000
New +$2.85M
ACHC icon
71
Acadia Healthcare
ACHC
$2.95B
$2.69M 0.26%
39,824
+27,200
+215% +$1.9M
INSP icon
72
Inspire Medical Systems
INSP
$1.73B
$2.28M 0.22%
17,000
-25,000
-60% -$4.73M
APLS
73
DELISTED
Apellis Pharmaceuticals
APLS
$2.12M 0.2%
55,395
-123,000
-69% -$5.57M
MOH icon
74
Molina Healthcare
MOH
$10.3B
$2.08M 0.2%
+7,000
New +$2.38M
TMDX icon
75
Transmedics
TMDX
$3.03B
$2.03M 0.2%
+13,500
New +$1.62M
1 2
3
4

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Rhenman & Partners Asset Management held 98 positions worth $1.04B, down 1.3% from $1.06B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rhenman & Partners Asset Management's Q2 2024 filing shows 14 new, 36 increased, 31 reduced and 5 closed positions. Its largest new stake was Edwards Lifesciences: 97,500 shares worth $9.01M. The largest sale was Cigna, an estimated $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q2 2024 buy was Edwards Lifesciences: 97,500 shares worth $9.01M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q2 2024, an estimated $31.8M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2024 reduction was Cigna, cutting an estimated $21.7M.
  • Rhenman & Partners Asset Management fully exited Shockwave Medical, Inc. Common Stock in Q2 2024, selling an estimated $20.8M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $1.04B portfolio in Q2 2024.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 5 in Q2 2024.
  • Rhenman & Partners Asset Management's portfolio value fell 1.3% quarter-over-quarter to $1.04B.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.